Skip to main content

01.12.2017 | Letter to the Editor | Ausgabe 1/2017 Open Access

Journal of Hematology & Oncology 1/2017

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Journal of Hematology & Oncology > Ausgabe 1/2017
Keichiro Mihara, Tetsumi Yoshida, Yoshifumi Takei, Naomi Sasaki, Yoshihiro Takihara, Junya Kuroda, Tatsuo Ichinohe
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13045-017-0488-x) contains supplementary material, which is available to authorized users.
Chimeric antigen receptor
Double-expressing lymphoma
Double-hit lymphoma
Green fluorescent protein
Peridinin chlorophyll protein complex

Letter to the Editor

Patients with B cell lymphoma bearing MYC translocation combined with an additional translocation involving other genes, such as BCL2, BCL3, BCL6, or CCND1, whose category is defined as double-hit lymphoma (DHL), have a dismal prognosis [ 1]. Li et al. reported that the prognosis of B cell lymphoma patients expressing concurrent MYC and BCL2 proteins without translocations was also dismal as well as that of DHL-bearing translocations of MYC/BCL2 genes in terms of the prognosis [ 14]. Thus, recent studies have expanded the concept to include double-expressing lymphoma (DEL) that co-overexpresses MYC protein with those proteins. Accordingly, we defined cytogenetic DHL and DEL as primary DHL. An adoptive T cell immunotherapy with anti-CD19 chimeric antigen receptors (CAR) has been clinically shown to exhibit marked cytotoxicity in patients with relapsed and refractory B cell lymphoid neoplasias [ 57]. We also developed anti-CD38-CAR and demonstrated its marked cytotoxicity against various hematological malignancies [ 8, 9]. However, it has not been elucidated whether CAR therapy could be effective for patients with cytogenetic DHL and DEL. Here, we revealed the marked cytotoxicity of anti-CD19- and/or anti-CD38-CAR T cells as well as the synergy of both CARs against primary DHL cells.
Cytogenetic DHL ( n = 3) or DEL ( n = 2) cells of the lymph nodes were collected from five patients (Table  1) after obtaining appropriate informed consent. CD19 + CD20 + lymphoma cells accounted for over 90% (90–97%). DHL (DEL) cell line cells, bearing the translocation of the IgH/MYC gene as well as overexpression of BCL2 protein (KPUM-UH1) or these primary cells were cultured in RPMI-1640 complete medium.
Table 1
Patients’ profiles and cytotoxicity of T cells expressing anti-CD19- or anti-CD38-CAR against primary DHL cells
Karyotype (major abnormalities)
aExpression of CD38 in CD19 + cells (%)
aSpecific cytotoxicity of anti-CD19-CAR T cells (%)
aSpecific cytotoxicity of anti-CD38-CAR T cells (%)
Patient 1
98.69 ± 0.37
92.67 ± 0.55
97.49 ± 0.19
Patient 2
add(8)(q24),t(8;14)(q24;q32), t(3;22)(q27;q11.2)
98.74 ± 0.59
95.53 ± 2.88
99.88 ± 0.73
Patient 3
97.37 ± 0.02
98.94 ± 0.03
99.60 ± 0.27
Patient 4
98.47 ± 0.26
98.26 ± 0.78
99.47 ± 0.04
Patient 5
97.14 ± 0.83
97.41 ± 0.16
97.70 ± 0.23
Specific cytotoxicity was evaluated by flow cytometry following the co-incubation of T cells bearing anti-CD19- or anti-CD38-CAR (E) with DHL cells (T) at an E:T ratio of 1:2 for 3 days. The cutoffs for positivity for BCL2, BCL6, or MYC were 50, 30, and 40% of the cells, respectively
ND not determined
aResults are the mean ± SD of three experiments
The cutoffs for immunohistochemical positivity for BCL2, BCL6, and MYC (Abcam, Cambridge, MA, USA) were 50, 30, and 40% of microscopically observed lymphoma cells, respectively. FISH analyses were performed by SRL (Tokyo, Japan).
The retroviral vector of anti-CD19- and anti-CD38-CAR was previously developed [ 810]. To produce a RD114-pseudotyped retrovirus, MSCV-IRES-EGFP-anti-CD19-CAR or MSCV-IRES-EGFP-anti-CD38-CAR, pEQ-PAM3(-E), and pRDF were used to co-transfect 293T cells with Lipofectamine plus (Invitrogen, Carlsbad, CA, USA). Peripheral blood mononuclear cells of donors were cultured for 48 h with 7 μg/ml PHA-M (Sigma, St Louis, MO, USA), 200 IU/ml interleukin-2 (PeproTech, London, UK) in the complete medium as described previously [ 810]. These T cells were retrovirally transduced in the presence of 4 μg/ml polybrene (Sigma) in a retronectin-coated tube (Takara-Bio, Otsu, Japan). For the transduction of anti-CD38-CAR, an anti-CD38 antibody (CPK-H; MBL, Nagoya, Japan) was added to the culture medium to protect transduced T cells from autolysis through cross-linkage of the anti-CD38-CAR with intrinsic CD38 [ 8, 9]. For the subsequent co-culture experiments, transduced T cells expressing green fluorescent protein (GFP) were sorted by FACSAria (BD). The specimens from patients and donors were used after approval by the institutional review board of Hiroshima University.
Primary DHL cells co-cultured with anti-CD19- and/or anti-CD38-CAR T cells were harvested and stained with an anti-CD19 antibody-PE and anti-CD38 antibody-APC (BD). These cells were then analyzed by a flow cytometer. Specific cytotoxicity of anti-CD19- and/or anti-CD38-CAR T cells against CD19 + primary DHL cells was evaluated using the formula (B-A)/B, where A is the number of CD19 + GFP cells or CD38 + GFP cells after incubation with anti-CD19- or anti-CD38-CAR-expressing T cells, respectively, and B is the number of CD19 + GFP or CD38 + GFP cells after incubation with vector-transduced T cells [ 810].
We initially detected cytogenetic DHL and DEL (Additional file 1: Figure S1 and Table  1). Next, we confirmed that goat anti-mouse-IgG-PerCP, which cross-reacts with CAR and GFP of the vector, were co-expressed as an internal control in T cells retrovirally transduced (transduction efficiency: 67.42 ± 14.43% ( n = 5) for anti-CD19-CAR, 63.21 ± 10.89% ( n = 5) for anti-CD38-CAR).
Prior to co-culture experiments, we examined whether CD19 + primary DHL cells expressed CD38. We showed that >97% of DHL cells obtained from five patients expressed CD38 (Table  1). DHL (DEL) cell line cells (KPUM-UH1) expressing CD19 and CD38 were co-cultured with anti-CD19- or anti-CD38-CAR T cells at an effector (E) target (T) ratio of 1:2 for 3 days. Co-culture experiments showed that either anti-CD19- or anti-CD38-CAR T cells almost completely eradicated KPUM-UH1 cells (Fig.  1a). As further experiments, CD19- or CD38-specific T cells were co-cultured with cytogenetic DHL ( n = 3) or DEL ( n = 2) cells from five patients at an E:T ratio of 1:2 for 3 days. Similarly, anti-CD19- or anti-CD38-CAR T cells completely abolished the primary DHL cells, respectively (Fig.  1a, c and Table  1). Using DHL cells from patient 2, we confirmed that each of the CAR T cells eliminated DHL cells in a cell-number-dependent manner (Fig.  1b, c). Additionally, anti-CD19-CAR T cells synergistically exerted a collaborative cytotoxicity against DHL cells from patient 2 with anti-CD38-CAR T cells, as shown in Fig.  1c. The simultaneous combination index was less than 1.0, leading to the synergy according to Calcusyn software (Biosoft, Cambridge, UK).
These results showed that primary DHL cells, which are refractory or resistant to existing chemotherapeutic agents, can be efficiently abrogated by the clinical use of T cells with anti-CD19- and/or anti-CD38-CAR. Taken together, these results may warrant adoptive immunotherapy with T cells transduced with anti-CD19- and/or anti-CD38-CAR for patients with refractory cytogenetic DHL and DEL.


We thank Sachiko Fukumoto and Ryoko Matsumoto (Department of Hematology and Oncology, Hiroshima University) for providing us with experimental assistance.


This study was supported in part by grants from the Ministry of Health, Labour, and Welfare of Japan.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

KM designed and performed the experiments, analyzed the data, and wrote the paper. JK provided us with KPUM-UH1 cells and comments on writing the paper. TY and YT analyzed the data. YT, NS, and TI helped write the manuscript. All authors contributed to the interpretation of the results. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The specimens from the patients and donors were used after obtaining appropriate informed consent and approval by the institutional review board of Hiroshima University.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Unsere Produktempfehlungen

e.Med Interdisziplinär


Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

e.Med Innere Medizin


Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie


Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl. 

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Journal of Hematology & Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.